JP2016514966A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016514966A5 JP2016514966A5 JP2016501985A JP2016501985A JP2016514966A5 JP 2016514966 A5 JP2016514966 A5 JP 2016514966A5 JP 2016501985 A JP2016501985 A JP 2016501985A JP 2016501985 A JP2016501985 A JP 2016501985A JP 2016514966 A5 JP2016514966 A5 JP 2016514966A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- subject
- sample
- computer readable
- prostate cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014509 gene expression Effects 0.000 claims description 100
- 206010060862 Prostate cancer Diseases 0.000 claims description 78
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 78
- 108090000623 proteins and genes Proteins 0.000 claims description 71
- 108091033411 PCA3 Proteins 0.000 claims description 30
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 claims description 29
- 101001077417 Gallus gallus Potassium voltage-gated channel subfamily H member 6 Proteins 0.000 claims description 28
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims description 28
- 101001010792 Homo sapiens Transcriptional regulator ERG Proteins 0.000 claims description 28
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims description 27
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 claims description 25
- 101000883686 Homo sapiens 60 kDa heat shock protein, mitochondrial Proteins 0.000 claims description 25
- 101000988394 Homo sapiens PDZ and LIM domain protein 5 Proteins 0.000 claims description 25
- 102100029181 PDZ and LIM domain protein 5 Human genes 0.000 claims description 25
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 25
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims description 24
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims description 23
- 101001076642 Homo sapiens Inosine-5'-monophosphate dehydrogenase 2 Proteins 0.000 claims description 21
- 102100025891 Inosine-5'-monophosphate dehydrogenase 2 Human genes 0.000 claims description 21
- 101001033610 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Inosine-5'-monophosphate dehydrogenase Proteins 0.000 claims description 21
- ZUPXXZAVUHFCNV-UHFFFAOYSA-N [[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [5-(3-carbamoyl-4h-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate;potassium Chemical compound [K].C1=CCC(C(=O)N)=CN1C1C(O)C(O)C(COP(O)(=O)OP(O)(=O)OCC2C(C(O)C(O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ZUPXXZAVUHFCNV-UHFFFAOYSA-N 0.000 claims description 21
- 101000662009 Homo sapiens UDP-N-acetylglucosamine pyrophosphorylase Proteins 0.000 claims description 19
- 102100037921 UDP-N-acetylglucosamine pyrophosphorylase Human genes 0.000 claims description 19
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 claims description 16
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims description 16
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims description 16
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 claims description 16
- 238000004422 calculation algorithm Methods 0.000 claims description 7
- 238000007477 logistic regression Methods 0.000 claims description 7
- 238000007637 random forest analysis Methods 0.000 claims description 7
- 238000013500 data storage Methods 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims 2
- 238000000338 in vitro Methods 0.000 description 79
- 238000001514 detection method Methods 0.000 description 73
- 239000000523 sample Substances 0.000 description 70
- 238000000034 method Methods 0.000 description 24
- 102100038358 Prostate-specific antigen Human genes 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 23
- 210000002700 urine Anatomy 0.000 description 21
- 108020004999 messenger RNA Proteins 0.000 description 17
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 6
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 6
- 238000011319 anticancer therapy Methods 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 238000011471 prostatectomy Methods 0.000 description 4
- 239000013074 reference sample Substances 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 201000004240 prostatic hypertrophy Diseases 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 101150076800 B2M gene Proteins 0.000 description 1
- 101150029838 ERG gene Proteins 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- 101150045036 petN gene Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361785375P | 2013-03-14 | 2013-03-14 | |
| US61/785,375 | 2013-03-14 | ||
| PCT/US2014/025860 WO2014160120A1 (en) | 2013-03-14 | 2014-03-13 | Compositions and methods for detecting and determining a prognosis for prostate cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016514966A JP2016514966A (ja) | 2016-05-26 |
| JP2016514966A5 true JP2016514966A5 (enExample) | 2017-04-13 |
| JP6285009B2 JP6285009B2 (ja) | 2018-02-28 |
Family
ID=51625336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501985A Expired - Fee Related JP6285009B2 (ja) | 2013-03-14 | 2014-03-13 | 前立腺ガンの予後の検知及び判定のための組成物及び該検知及び判定方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140336280A1 (enExample) |
| EP (1) | EP2971177B1 (enExample) |
| JP (1) | JP6285009B2 (enExample) |
| CN (1) | CN105102636B (enExample) |
| CA (1) | CA2904088A1 (enExample) |
| WO (1) | WO2014160120A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11105808B2 (en) | 2004-11-12 | 2021-08-31 | Health Discovery Corporation | Methods for screening, predicting and monitoring prostate cancer |
| CN104561303A (zh) * | 2014-12-31 | 2015-04-29 | 南京卡迪奥密生物技术有限公司 | 人肿瘤预测性生物标志组合物及其应用 |
| WO2017103047A1 (en) * | 2015-12-17 | 2017-06-22 | Institut Curie | Use of antisense long non-coding rnas for the diagnosis of prostate cancer |
| CN106282366A (zh) * | 2016-09-09 | 2017-01-04 | 北京致成生物医学科技有限公司 | 一种与前列腺癌相关的分子标记物及其应用 |
| CN106148554A (zh) * | 2016-09-09 | 2016-11-23 | 北京致成生物医学科技有限公司 | 一种用于前列腺癌检测的标志物及其在试剂盒中的应用 |
| CN106148556A (zh) * | 2016-09-14 | 2016-11-23 | 北京致成生物医学科技有限公司 | C22orf41在前列腺癌诊断标志物中的应用 |
| CN106282382A (zh) * | 2016-09-30 | 2017-01-04 | 北京致成生物医学科技有限公司 | Loc100128842在制备诊断或预示前列腺癌产品中的用途 |
| JP2019531738A (ja) * | 2016-10-14 | 2019-11-07 | ウニヴェルズィテート チューリッヒ | 前立腺癌の診断と予後のためのインドールアミン−２，３−ジオキシゲナーゼ アッセイ |
| JP6812789B2 (ja) * | 2016-12-28 | 2021-01-13 | 富士通株式会社 | 情報処理装置、情報処理プログラム、および情報処理方法 |
| CN110760584B (zh) * | 2019-11-07 | 2022-12-09 | 深圳市华启生物科技有限公司 | 前列腺癌疾病进展生物标志物及其应用 |
| CN110760585B (zh) * | 2019-11-07 | 2022-12-09 | 深圳市华启生物科技有限公司 | 前列腺癌生物标志物及其应用 |
| US20210333280A1 (en) * | 2020-04-23 | 2021-10-28 | YatHing Biotechnology Company Limited | Methods related to the diagnosis of prostate cancer |
| US20240011996A1 (en) * | 2020-11-24 | 2024-01-11 | Korea Institute Of Science And Technology | Biomarkers for diagnosing prostate cancer, combination thereof, and use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005245815B2 (en) | 2004-05-07 | 2011-06-09 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer |
| EP1824995A2 (en) * | 2004-11-24 | 2007-08-29 | St. George's Enterprises Limited | Diagnosis of prostate cancer |
| US8288110B2 (en) * | 2006-12-04 | 2012-10-16 | Perkinelmer Health Sciences, Inc. | Biomarkers for detecting cancer |
| EP2373816B1 (en) | 2008-12-04 | 2014-05-21 | Health Discovery Corporation | Methods for screening, predicting and monitoring prostate cancer |
| WO2010065940A1 (en) * | 2008-12-04 | 2010-06-10 | The Regents Of The University Of California | Materials and methods for determining diagnosis and prognosis of prostate cancer |
| EP3524697B1 (en) * | 2009-01-07 | 2024-10-02 | Myriad Genetics, Inc. | Cancer biomarkers |
| US20120041274A1 (en) * | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
| US20130058925A1 (en) * | 2010-02-26 | 2013-03-07 | Board Of Regents, The University Of Texas System | Epithelial biomarkers for cancer prognosis |
| AU2011352167A1 (en) | 2010-12-28 | 2013-07-11 | Caris Mpi, Inc. | Molecular profiling for cancer |
| WO2012092490A1 (en) * | 2010-12-30 | 2012-07-05 | Quest Diagnostics Investments Incorporated | Diagnosis of prostate cancer |
| CA2827894A1 (en) | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
| US20140066325A1 (en) * | 2011-03-17 | 2014-03-06 | The Brigham And Women's Hospital, Inc. | Protein Biomarkers for the Diagnosis of Prostate Cancer |
| WO2012135008A1 (en) * | 2011-03-26 | 2012-10-04 | Oregon Health And Science University | Gene expression predictors of cancer prognosis |
| CN102912030B (zh) * | 2012-11-08 | 2014-07-30 | 端鹏 | 用于前列腺癌早期诊断的引物对、探针和试剂盒 |
-
2014
- 2014-03-13 WO PCT/US2014/025860 patent/WO2014160120A1/en not_active Ceased
- 2014-03-13 CA CA2904088A patent/CA2904088A1/en not_active Abandoned
- 2014-03-13 US US14/208,850 patent/US20140336280A1/en not_active Abandoned
- 2014-03-13 EP EP14775449.3A patent/EP2971177B1/en active Active
- 2014-03-13 JP JP2016501985A patent/JP6285009B2/ja not_active Expired - Fee Related
- 2014-03-13 CN CN201480015039.9A patent/CN105102636B/zh not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016514966A5 (enExample) | ||
| CA2923092C (en) | Assessment of the pi3k cellular signaling pathway activity using mathematical modelling of target gene expression | |
| JP2022532892A (ja) | モデルベースの特徴量化および分類 | |
| JP7654538B2 (ja) | 転写因子プロファイリング | |
| Alanee et al. | Contemporary incidence and mortality rates of neuroendocrine prostate cancer | |
| Appel et al. | Current staging systems for pancreatic cancer | |
| US20200232046A1 (en) | Genomic sequencing classifier | |
| Kage et al. | Small lung tumor biopsy samples are feasible for high quality targeted next generation sequencing | |
| JP2015503330A (ja) | 多重遺伝子バイオマーカーの同定 | |
| Galvano et al. | Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis | |
| Saltman et al. | Prostate cancer biomarkers and multiparametric MRI: is there a role for both in prostate cancer management? | |
| Kawaguchi et al. | Gene Expression Signature–Based Prognostic Risk Score in Patients with Primary Central Nervous System Lymphoma | |
| Shapiro et al. | Prediction of survival in patients with oesophageal or junctional cancer receiving neoadjuvant chemoradiotherapy and surgery | |
| Mengual et al. | Validation study of a noninvasive urine test for diagnosis and prognosis assessment of bladder cancer: evidence for improved models | |
| JP2018527886A5 (enExample) | ||
| JP2024523848A (ja) | 癌検出方法、キットおよびシステム | |
| Ryu et al. | Deciphering intratumor heterogeneity using cancer genome analysis | |
| Wan et al. | Diagnostic significance of circulating long noncoding RNA PCAT6 in patients with non-small cell lung cancer | |
| Oh et al. | A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity | |
| Kay et al. | The role of nodes and nodal assessment in diagnosis, treatment and prediction in ER+, node-positive breast cancer | |
| Nakauchi et al. | Development of a prediction model for lymph node metastasis in luminal A subtype breast cancer: the possibility to omit sentinel lymph node biopsy | |
| Syed et al. | Current management strategy for active surveillance in prostate cancer | |
| US20220213558A1 (en) | Methods and systems for urine-based detection of urologic conditions | |
| Cucchetti et al. | Impact of primary cancer features on behaviour of colorectal liver metastases and survival after hepatectomy | |
| Aiolfi et al. | Effect of complete mesocolic excision (cme) on long-term survival after right colectomy for cancer: multivariate meta-analysis and restricted mean survival time estimation |